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Background: Circulating DNA is observed at higher concentrations in
patients with lung cancer than in controls. Qualitative and quantitative
analysis of circulating DNA is a promising noninvasive tool. Our aim
was to prospectively study the association between the catalytic subunit
of telomerase (human telomerase reverse transcriptase [hTERT]) in
plasma and clinical variables and survival in a large-scale non-small cell
lung cancer (NSCLC) study.
Methods: Four hundred forty-six patients with stages IIIB and IV
NSCLC with a median follow-up of 9.7 months (range, 0.5–45)
were analyzed. Blood samples were collected before therapy start
(cisplatin/docetaxel). Quantification of baseline circulating DNA
was determined as the amount of free hTERT in plasma, by using
real-time quantitative polymerase chain reaction.
Results: Patients with hTERT 49.8 ng/ml (median value) had a
median time to progression (TTP) of 6.3 months compared with 4.9 for
hTERT more than 49.8 ng/ml (p  0.001). Overall survival (OS) was
significantly higher (10.9 versus 9.3 months) at lower hTERT levels
(p 0.012). When calculations were done using hTERT as continuous
variable, we did not observe independent significant differences. Thus,
there is an apparent discrepancy in p values when hTERT is considered
as a continuous versus dichotomized variable. There was a tendency to
differentiate median hTERT levels with respect to response rates (com-
plete response  partial response: 33.1 versus stable disease  pro-
gressive disease: 50.7 ng/ml, p 0.12), but other clinical variables such
as age, gender, performance status, stage, histology, and number of
metastatic locations were not associated with hTERT. In multivariate
analysis, hTERT was an independent prognostic variable for both TTP
(hazard ratio: 1.44, p 0.001) and OS (hazard ratio: 1.33, p 0.007).
Conclusions: In advanced NSCLC, high pretreatment circulating
hTERT level is an independent poor prognostic marker for TTP and
OS. Circulating DNA is a noninvasive marker, which may help to
improve the prognostic profile of these patients.
Key Words: hTERT, Telomerase, Plasma, Prognostic factors, Non-
small cell lung cancer, NSCLC.
(J Thorac Oncol. 2011;6: 286–290)
During carcinogenesis, pathologic tissue liberates cells andcell components to the blood stream, even at early stages of
the disease.1–3 The presence of nucleic acids in blood was
reported more than 30 years ago by Leon et al.4 In the late 1990s,
Kopreski et al.5,6 found that patients with cancer have more free
DNA and RNA in the plasma or serum than healthy subjects.
The origin of this genetic material was not well estab-
lished, but research up to now has confirmed a high degree of
correlation between the genetic changes in the tumor and those
detected in the blood,7–9 which supports that much of the
circulating DNA in the patients with cancer derives from the
tumor.10 These observations laid the foundation for the de-
velopment of cell-free DNA/RNA assays for early detection
of cancer and for aid in diagnosis,11–13 although critical
voices have been raised against its relevance for screening
and diagnostics.14,15
During cancer, however, determination of plasma- or
serum-free DNA may be an important prognostic factor with
respect to treatment and posttherapy follow-up.16,17 The amount
of free human telomerase reverse transcriptase (hTERT) in
plasma serves as a surrogate of circulating DNA. This test is
easily and noninvasively performed at any time during therapy
or follow-up and requires only a limited blood sample. Never-
theless, the prognostic role has been questioned because some
studies demonstrate an association with survival,18,19 whereas
others do not.16,20,21
Although the levels of circulating cell-free DNA in
plasma or serum are higher in patients with lung cancer than in
healthy controls, hitherto it is not resolved whether this will be
of diagnostic or prognostic value. Neither has the association
*Department of Biotechnology, Universidad Polite´cnica de Valencia; †Mo-
lecular Oncology Laboratory, Fundacio´n Investigacio´n, Hospital General
Universitario, Valencia, Spain; ‡Institute of Clinical Medicine, Univer-
sity of Tromsø; §Department of Oncology, University Hospital of North
Norway, Tromsø, Norway; Department of Medical Oncology, Hospital
General Universitario, Valencia; ¶The Catalan Oncology Institute, Hos-
pital Universitari Germans Trias i Pujol, Badalona, Barcelona; #Depart-
ment of Thoracic Surgery, Hospital General Universitario, Valencia; and
**Department of Preventive Medicine, Universidad Auto´noma de Ma-
drid, Madrid, Spain.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Dr. Carlos Camps, Servicio de Oncología
Me´dica, Hospital General Universitario de Valencia, Av. Tres Cruces s/n,
Valencia 46014, Spain. E-mail: camps_car@gva.es
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0602-0286
Journal of Thoracic Oncology • Volume 6, Number 2, February 2011286
with clinicopathological variables such as age, gender, perfor-
mance status, and stage of disease been established.
The objective of our study was to quantify the amount of
the hTERT gene in cell-free DNA in plasma from a large-scale
cohort of patients with non-small cell lung cancer (NSCLC) and
to correlate hTERT with time to progression (TTP) and overall
survival (OS), and clinicopathological variables.
MATERIALS AND METHODS
Patients
This study has been performed with blood samples from
446 patients diagnosed with advanced stage (IIIB–IV) NSCLC
who were enrolled in a multicenter clinical trial of the Spanish
Lung Cancer Group between February 2003 and January 2005.
The patients were chemonaive at inclusion. Blood samples were
obtained before the planned start of combination chemotherapy
with cisplatin and docetaxel. The institutional ethical review
board approved the study.
Sample Collection and DNA Isolation
All patients were sampled before chemotherapy; 10-ml
samples of peripheral blood were collected in vacutainer tubes
containing ethylenediaminetetraacetic acid as anticoagulant
(Becton Dickson, NJ) for plasma recovery. Tubes were sent to
the reference laboratory, and in less than 24 hours, ethylenedia-
minetetraacetic acid-blood samples were subjected to two cen-
trifugation steps: an initial centrifugation for 10 minutes at
1100g at room temperature and a second centrifugation of the
supernatants for 10 minutes at 2000g at room temperature. This
plasma was stored at 80°C until further analysis.
Free DNA was extracted and purified from 400 l of
plasma by using commercial DNA affinity columns (QIAamp-
Blood Mini Kit, QIAGEN, Chatsworth, CA), following the
manufacturer’s recommendations, and eluted in 60 l of kit’s
elution buffer.
DNA Quantification in Plasma
The plasma-free DNA concentration was measured by
using a previously described highly reproducible quantitative
real-time polymerase chain reaction targeting the hTERT gene.22
The two primers and the minor groove binding probe were
designed to amplify specifically the gene of interest, hTERT,
generating an amplicon of 98 base pairs. The sequences, syn-
thesized by Applied Biosystems, Foster City, CA were as
follows:
Forward primer: 5 GGC ACA CGT GGC TTT TCG-3
Reverse primer: 5 GGA GAG CAG AGG CAG AGA
TCA-3
Minor groove binding probe: 6-FAM- 5 TCC ACT CGA
CGT CCT GA-3
The reaction was done in 96-well plates with a total
volume of 50 l/well, as described previously.22 A standard
curve using genomic human DNA from 50 pg to 50 ng (Applied
Biosystems) was added to every amplification plate as described
previously.22
Statistical Analysis
hTERT was analyzed as a continuous and dichotomized
variable. For the dichotomized hTERT variable, the cutoff level
for low and high values was set at the median. The Kolgomorov-
Smirnov test was used to examine whether a continuous hTERT
variable or its transformations followed a normal distribution. A
Martingale residual analysis was run to check whether there was
a linear trend between hTERT levels and survival. TTP and
survival were also compared with tercils of hTERT concentra-
tions. As hTERT values did not show a normal distribution, the
comparisons were done with the nonparametric Mann-Whitney
U test and Kruskal-Wallis test and the Spearman nonparametric
correlation analysis. OS was calculated from the time of diag-
nosis and TTP from the date of treatment start. OS and TTP
were calculated using the Kaplan-Meier model, and differences
between groups were assessed by the log-rank test. For the
multivariate analysis, we used Cox-regression analysis. All sta-
tistically significant variables from the univariate analyses were
entered into the multivariate Cox analysis. A p value below 0.05
was considered statistically significant.
RESULTS
Table 1 lists the detailed demographic and clinicopatho-
logic characteristics of the patient population. The median age
TABLE 1. Patient Characteristics, Time to Progression, and
Survival of 446 Patients with Advanced NSCLC
Variables n Percentage
Time to
Progression
Overall
Survival
Median
(mo) p
Median
(mo) p
Age (yr)
Median (range) 60 (31–80) 0.17 0.39
60 yr 228 51 5.3 9.7
60 yr 218 49 5.9 10.8
Gender
Male 375 84 5.3 0.010 9.7 0.018
Female 71 16 6.7 13.5
ECOG PS
0 113 25 6.6 0.025 13.1 0.001
1–2 331 75 5.3 9.2
Missing 2
Histology
Adenocarcinoma 222 50 5.6 0.30 9.9 0.69
Squamous
carcinoma
139 31 5.6 10.8
Large cell
carcinoma
69 15 5.8 9.7
Undifferentiated 16 4 4.2 7.7
Stage
IIIB 70 16 5.5 0.26 10.2 0.86
IV 376 84 5.6 10.0
hTERT
49.8 ng/ml 223 50 6.3 0.001 10.9 0.012
49.8 ng/ml 223 50 4.9 9.3
NSCLC, non-small cell lung cancer; ECOG PS, Eastern Cooperative Oncology
Group performance stage.
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was 60 years, and 84% of the patients were men. The majority
of patients was in performance stage 1 (performance stage 1:
74%, performance stage 2: 1%), 50% had adenocarcinoma,
whereas 84% had stage IV NSCLC. Objective response was
seen in 27% (complete response: 0.7%, partial response: 26%),
whereas 73% had stable or progressive disease. TTP and OS
with respect to the clinicopathological variables are also pre-
sented in Table 1.
hTERT levels ranged widely from 0.8 to 43,735 ng/ml.
The median for the whole patient population was 49.8 ng/ml.
The continuous hTERT variable did not follow a normal
distribution even after a square root transformation. Using the
Martingale residuals analysis, there was no linear trend be-
tween hTERT levels and survival, indicating that the median
value as cutoff may not be justified.
There were no significant associations between plasma
hTERT concentrations and clinical characteristics such as age
(p  0.61), performance status (PS, p  0.48), gender (p 
0.51), stage (p  0.84), histology (p  0.23), and number of
metastatic locations (p  0.25). There was a significant associ-
ation between plasma hTERT concentrations and response to
treatment (p  0.043, Table 2). Complete response  partial
response patients (33.1 ng/ml) had a significantly lower median
pretreatment hTERT level, when compared with progressive
disease (63.7 ng/ml, p  0.036) but not stable disease patients
(45.3, p 0.52, Table 2). Progressive disease patients, however,
had significantly higher hTERT levels than stable disease pa-
tients (p  0.035, Table 2).
Using dichotomized hTERT levels TTP was significantly
associated with plasma hTERT. Patients with pretreatment
hTERT concentration 49.8 ng/ml had a median TTP of 6.3
months, whereas those more than 49.8 ng/ml had median TTP of
4.9 months (p  0.001, Figure 1). When the material was
divided according to tercils of hTERT plasma concentrations,
TTP was 7.0, 4.7, and 5.3 months at first, second, and third
tercils, respectively (p  0.003). Patients with hTERT 49.8
ng/ml had a median OS of 10.9 months, whereas those more
than 49.8 ng/ml had a median OS of 9.3 months (p  0.012,
Figure 2). According to tercils, median survival was 12.7, 9.6,
and 9.8 months at first, second, and third tercils, respectively
(p  0.013).
To identify significant individual prognostic markers,
Cox regression analysis was performed. Using the dichoto-
mized hTERT variable, multivariate analysis revealed that
plasma hTERT level (hazard ratio [HR]: 1.44, 95% confi-
dence interval [CI]: 1.18–1.75, p  0.001), Eastern Cooper-
ative Oncology Group PS (HR: 1.31, 95% CI: 1.04–1.64, p
0.017), and gender (HR: 1.46, 95% CI: 1.11–1.91, p 0.005)
had an independent prognostic role (Table 2). With respect to
OS, plasma hTERT level (HR: 1.33, 95% CI: 1.08–1.63, p 
0.007), Eastern Cooperative Oncology Group PS (HR: 1.56,
95% CI: 1.22–1.99, p  0.001), and gender (HR: 1.51, 95%
CI: 1.12–2.02, p  0.004) were independent prognosticators
(Table 3). When square root transformed continuous hTERT
variable was entered in the Cox regression analysis, hTERT
TABLE 2. hTERT Plasma Levels According to Objective
Response Rates
n
Median
(ng/ml)
Mean
(ng/ml)
Range
(ng/ml) pa pb
CR  PR 110 33.1 219 1.2–3172.5 0.043
SD 145 45.3 385 2.2–9648.3 0.52c; 0.035d
PD 155 63.7 632 0.8–43735.2 0.036e
a Kruskal-Wallis test.
b Mann-Whitney U test.
c CR  PR vs. SD.
d SD vs. PD.
e CR  PR vs. PD.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
FIGURE 1. Time to progression according to pretreatment
median hTERT plasma levels.
FIGURE 2. Overall survival according to pretreatment me-
dian hTERT plasma levels.
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was not an independent prognosticator for survival (HR:
1.003, 95% CI: 0.99–1.009, p  0.30).
DISCUSSION
In 446 patients with advanced NSCLC, we investigated
the prognostic role of circulating DNA (hTERT) in plasma
sampled immediately before chemotherapy start. It was ob-
served that plasma hTERT concentrations were significantly
associated with the objective response rates. Using the median
value as cutoff level, we found hTERT to be a significant
independent prognostic factor for both TTP and OS. Neverthe-
less, this could not be reproduced when the continuous hTERT
variable was used.
The strength of this study is the population size, in
contrast to previous studies where the investigated cohorts, in
general, have numbered 100 individuals or less. The lack of
healthy control samples may be a weakness but of less
importance in established advanced NSCLC than for screen-
ing purposes in healthy individuals.
Although the presence of nucleic acids in blood was
reported more than 30 years ago,4 the interest were significantly
aroused at the publication in 2003 by Sozzi et al.13,23 of plasma
hTERT data from 100 patients with NSCLC and 100 age-,
sex-, and smoking-matched controls. They found signifi-
cantly higher levels of free circulating DNA in patients with
NSCLC than in disease-free heavy smokers and concluded
that this method should be used as a new approach for early
detection of lung cancer.
Research into the role of circulating DNA in established
cancers has demonstrated a strong power to discriminate patients
with lung cancer from those with benign lung diseases or healthy
individuals.24,25 It has further confirmed a high degree of corre-
lation between genetic changes in tumors and those detected in
the blood.10,15,26–29 These findings support the hypothesis that a
significant portion of the circulating DNA in patients with
cancer are derived from the tumor. In a thorough review,
Fleischhacker and Schmidt10 concluded that because these free
circulating DNAs are a reflexion of the physiological and patho-
logic processes in the human body, it makes them a very
interesting target for the development of clinically useful assays.
In several nonlung malignancies such as colorectal, breast,
and prostate cancer, enhanced blood DNA levels have been
shown to correlate with prognosis.29–31 In NSCLC, there are
conflicting data concerning the prognostic role of circulating
hTERT in these patients. Three clinical studies,16,20,21 of which
the study by Sozzi et al.16 is the largest with 84 patients with
NSCLC, did now show an association with survival. Ludovini et
al.,21 in 76 operable stage I to III patients with NSCLC, found that
circulating DNA declined after surgery and increased at recurrence,
even though it did not show any prognostic significance.
In this study, we observed that high hTERT levels were
significant and independent prognosticators for TTP and OS
when the dichotomized variable was used. When calculations
were done using the continuous variable, we did not observe
independent significant differences. Thus, there is an apparent
discrepancy in p values when hTERT is considered as a contin-
uous versus dichotomized variable. Nevertheless, increasing
pretreatment plasma concentrations of hTERT was significantly
associated with later reduced chemotherapy efficacy, which
supports the survival differences based on hTERT cutoffs at the
median value. It may be argued that the prognostic impact by
plasma hTERT levels not necessarily is mediated by linear changes
in hTERT levels. It should be noted that the significant associations
between hTERT tercils versus both TTP and survival supports our
results using the dichotomized hTERT variable.
The DNA concentrations in our study did not seem to be
influenced by either pretreatment tumor characteristics or clini-
cal variables such as age and gender. In a recent study on 46
patients with NSCLC, van der Drift et al.32 observed that high
circulating DNA levels correlated with a worse survival, con-
sistent with our results. Also, they did not find any relationship
of DNA concentration with tumor or clinical variables. In a
larger NSCLC cohort of 185 patients with NSCLC, Gautschi et
al.19 reported high baseline plasma DNA to correlate with poor
survival, advanced tumor stage, lactate dehydrogenase level, and
leukocytes. They also observed that high DNA levels correlated
to disease progression, in agreement with the independent prog-
nostic relevance the higher dichotomized hTERT level had for
TTP in our study. Fournie´ et al.18 examined the plasma DNA
levels in 68 hospitalized patients with lung cancer, of which 46
has NSCLC. Also in this study, high circulating DNA levels are
TABLE 3. Results of Cox Regression Analysis Summarizing
Significant Independent Prognostic Factors Regarding Time
to Progression (TTP)
Factors Hazard Ratio 95% CI p
Gender
Female 1.00 0.005
Male 1.46 1.11–1.91
hTERT
49.8 ng/ml 1.00 0.001
49.8 ng/ml 1.44 1.18–1.75
ECOG PS
0 1.00 0.017
1–2 1.31 1.04–1.64
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance stage.
TABLE 4. Results of Cox Regression Analysis Summarizing
Significant Independent Prognostic Factors with Respect to
Overall Survival
Factor Hazard Ratio 95% CI p
ECOG PS
0 1.00 0.001
1–2 1.56 1.22–1.99
Gender
Female 1.00 0.004
Male 1.51 1.12–2.02
hTERT
49.8 ng/ml 1.00 0.007
49.8 ng/ml 1.33 1.08–1.63
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance stage.
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related to poor OS and advanced disease stage. In a recently
published lung cancer screening study, Sozzi et al.33 also ob-
served poor survival at high plasma DNA concentration.
Possible reasons for discrepancies regarding the prognos-
tic impact of hTERT may be choice of patient population and
sample processing. Some studies have included both small cell
lung cancer and NSCLC, which differ largely in biology, treat-
ment, and prognosis.20,18 Most studies have included patients
with both advanced and limited surgical disease,18,19,32 whereas
only patients with advanced NSCLC (IIIB and IV) were in-
cluded in this study. This variability may, in part, explain why
there was no correlation between hTERT levels and disease stage
in our study. Disparities in levels of circulating DNA between
studies are primarily due to protocol differences with respect to
blood sample processing, DNA extraction, and DNA quanti-
fication method. Although most researchers today use quan-
titative polymerase chain reaction for DNA quantification,
there is still a considerable potential for further standardiza-
tion of sample source, sample processing, and DNA extrac-
tion methods.10,23
Using a dichotomized hTERT variable, we conclude that a
high baseline level of circulating hTERT is a significant inde-
pendent prognosticator for poor TTP and OS in advanced
NSCLC. This is supported by significant negative associations
between plasma hTERT concentrations and objective response
rates, and by the association between hTERT tercils versus both
TTP and survival. Furthermore, the hTERT concentration was
not influenced by tumor characteristics or clinical variables.
hTERT analysis requires a simple, noninvasive, and affordable
procedure, and it may aid in therapy evaluations and follow-up
of patients with NSCLC.
ACKNOWLEDGMENTS
Supported, in part, by the Spanish Society of Medical
Oncology (SEOM).
REFERENCES
1. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity
in cancer patients. Cancer Res 2003;63:3966–3968.
2. Silva JM, Silva J, Sanchez A, et al. Tumor DNA in plasma at diagnosis
of breast cancer patients is a valuable predictor of disease-free survival.
Clin Cancer Res 2002;8:3761–3766.
3. Anker P, Stroun M. Tumor-related alterations in circulating DNA,
potential for diagnosis, prognosis and detection of minimal residual
disease. Leukemia 2001;15:289–291.
4. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of
cancer patients and the effect of therapy. Cancer Res 1977;37:646–650.
5. Kopreski MS, Benko FA, Kwee C, et al. Detection of mutant K-ras DNA
in plasma or serum of patients with colorectal cancer. Br J Cancer
1997;76:1293–1299.
6. Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening:
identification of individuals harboring K-ras mutations with the use of
plasma DNA. J Natl Cancer Inst 2000;92:918–923.
7. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma
of cancer patients: quantitations and evidence for their origin from
apoptotic and necrotic cells. Cancer Res 2001;61:1659–1665.
8. Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in
plasma/serum of lung cancer patients as a potential screening and
prognostic tool. Clin Chem 2006;52:1833–1842.
9. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the
DNA found in the plasma of cancer patients. Oncology 1989;46:318–
322.
10. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and
cancer—a survey. Biochim Biophys Acta 2007;1775:181–232.
11. Ramirez JL, Taron M, Balan˜a C, et al. Serum DNA as a tool for cancer
patient management. Rocz Akad Med Bialymst 2003;48:34–41.
12. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new
diagnostic gold mine? Cancer Treat Rev 2002;28:255–271.
13. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA
as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902–3908.
14. Altundag O, Altundag K, Altundag M. Free circulating DNA: good as a
diagnostic marker in lung cancer? J Clin Oncol 2004;22:3201–3202.
15. Teare MD, Woll PJ. Genomic tests: unreliable for cancer? A focus on
circulating DNA and lung cancer. Expert Rev Mol Diagn 2007;7:699–
702.
16. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA
in plasma at diagnosis and during follow-up of lung cancer patients.
Cancer Res 2001;61:4675–4678.
17. Chen X, Bonnefoi H, Diebold-Berger S, et al. Detecting tumor-related
alterations in plasma or serum DNA of patients diagnosed with breast
cancer. Clin Cancer Res 1999;5:2297–2303.
18. Fournie´ GJ, Courtin JP, Laval F, et al. Plasma DNA as a marker of
cancerous cell death. Investigations in patients suffering from lung
cancer and in nude mice bearing human tumours. Cancer Lett 1995;91:
221–227.
19. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic
acid as prognostic marker in non-small-cell lung cancer patients under-
going chemotherapy. J Clin Oncol 2004;22:4157–4164.
20. Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatel-
lite panel as sensitive and tumor-specific marker in lung cancer patients.
Int J Cancer 2003;105:361–370.
21. Ludovini V, Pistola L, Gregorc V, et al. Plasma DNA, microsatellite
alterations, and p53 tumor mutations are associated with disease-free
survival in radically resected non-small cell lung cancer patients: a study
of the perugia multidisciplinary team for thoracic oncology. J Thorac
Oncol 2008;3:365–373.
22. Camps C, Sirera R, Bremnes RM, et al. Quantification in the serum of
the catalytic fraction of reverse telomerase: a useful prognostic factor in
advanced non-small cell lung cancer. Anticancer Res 2006;26:4905–
4909.
23. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and
RNA markers in blood: a tool for early detection, diagnostics, and
follow-up? Lung Cancer 2005;49:1–12.
24. Maebo A. [Plasma DNA level as a tumor marker in primary lung
cancer]. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1085–1091.
25. Xie GS, Hou AR, Li LY, et al. Quantification of plasma DNA as a
screening tool for lung cancer. Chin Med J (Engl) 2004;117:1485–1488.
26. Fujita Y, Fujikane T, Fujiuchi S, et al. The diagnostic and prognostic
relevance of human telomerase reverse transcriptase mRNA expression
detected in situ in patients with nonsmall cell lung carcinoma. Cancer
2003;98:1008–1013.
27. Komiya T, Kawase I, Nitta T, et al. Prognostic significance of hTERT
expression in non-small cell lung cancer. Int J Oncol 2000;16:1173–
1177.
28. Coulet F, Blons H, Cabelguenne A, et al. Detection of plasma tumor
DNA in head and neck squamous cell carcinoma by microsatellite typing
and p53 mutation analysis. Cancer Res 2000;60:707–711.
29. Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in
plasma of breast cancer patients: clinicopathological correlations.
Cancer Res 1999;59:3251–3256.
30. Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in
plasma of patients with metastatic spread in prostate cancer. Cancer Lett
2004;205:173–180.
31. Lecomte T, Berger A, Zinzindohoue´ F, et al. Detection of free-circulat-
ing tumor-associated DNA in plasma of colorectal cancer patients and its
association with prognosis. Int J Cancer 2002;100:542–548.
32. van der Drift MA, Hol BE, Klaassen CH, et al. Circulating DNA is a
non-invasive prognostic factor for survival in non-small cell lung cancer.
Lung Cancer 2010;68:283–287.
33. Sozzi G, Roz L, Conte D, et al. Plasma DNA quantification in lung
cancer computed tomography screening: five-year results of a prospec-
tive study. Am J Respir Crit Care Med 2009;179:69–74.
Sirera et al. Journal of Thoracic Oncology • Volume 6, Number 2, February 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer290
